Condition: Ovarian Cancer · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
This description comes directly from the study's public registry record.
Yuanchao Wang · 0518-82342973 · yuanchao.wang@hengrui.com
Always discuss trial participation with your own doctor first.
| Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06828354